Insider buying at Valeant ....... Good sign The Company has disclosed insider buying and selling activities to the Securities Exchange, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (Executive Vice President) of Valeant Pharmaceuticals International, Inc., Rosiello Robert L., had purchased 12,900 shares in a transaction dated on June 12, 2015. The transaction was executed at $232.51 per share with total amount equaling $2,999,379. Company has received recommendation from many analysts. BTIG Research initiates coverage on Valeant Pharmaceuticals International, Inc. (NYSE:VRX) The current rating of the shares is Buy. Equity Analysts at the Firm announces the price target to $275 per share. The rating by the firm was issued on July 20, 2015.